(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
-0.07% $ 22.24
Live Chart Being Loaded With Signals
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA)...
Stats | |
---|---|
Volumen de hoy | 4 015.00 |
Volumen promedio | 25 287.00 |
Capitalización de mercado | 69.36M |
EPS | $0 ( 2024-03-28 ) |
Próxima fecha de ganancias | ( $-1.000 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.35 |
ATR14 | $0.122 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Cataldi Fabio | Buy | 21 138 | Restricted Stock Unit |
2024-02-29 | Oakes Gregory | Buy | 54 454 | Restricted Stock Unit |
2023-05-30 | Batycky Alka | Buy | 3 600 | Stock Option (right to buy) |
2023-05-30 | Batycky Alka | Buy | 0 | |
2023-05-23 | Mayleben Timothy M | Buy | 18 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
96.61 |
Last 91 transactions |
Buy: 96 412 664 | Sell: 25 476 546 |
Landos Biopharma, Inc. Correlación
10 Correlaciones Más Positivas | |
---|---|
PRVB | 0.983 |
CDXC | 0.973 |
APOP | 0.964 |
DRNA | 0.961 |
ACTG | 0.958 |
GERN | 0.95 |
VTVT | 0.947 |
SIGA | 0.946 |
DXPE | 0.944 |
FUSN | 0.942 |
10 Correlaciones Más Negativas | |
---|---|
SBNYP | -0.974 |
RMGC | -0.954 |
BTTX | -0.954 |
ATAK | -0.945 |
AZ | -0.943 |
WKSP | -0.942 |
PHCF | -0.941 |
NLSP | -0.941 |
LUNA | -0.938 |
LIAN | -0.938 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Landos Biopharma, Inc. Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-3.50 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-3.50 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-577 000 (0.00 %) |
EPS: | $-9.44 |
FY | 2021 |
Ingresos: | $18.00M |
Beneficio Bruto: | $18.00M (100.00 %) |
EPS: | $-0.981 |
Financial Reports:
No articles found.
Landos Biopharma, Inc.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico